Launch of Dapsone 5%, Gel in the United States
Filed with ASX · · 1 page · English
Summary by 6ix AI
This topical prescription product is used to treat acne vulgaris and is part of Acrux's commercial pipeline. CEO Michael Kotsanis expressed excitement about this launch and future regulatory approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- Investor Presentation Half Year Accounts
- Appendix 4D and Half Year Accounts
- Appendix 4C and Activities Statement
- Address of Chair and CEO to AGM
- Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
Later from Acrux
- Acrux presentation at Hidden Gems in Lifesciences Forum
- RDTI funding facility secured
- Acrux presentation to Bioshares, 18th Biotech Summit
- Quarterly Activities Report and Appendix 4C - June 2024
- FDA Approval received for Dapsone Gel, 7.5%
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux